Improving practice . . . Advancing patient care  
 

American Urological Association Clinical Guidelines on Overactive Bladder (OAB) for Urologists: A Panel Webcast

Title:

American Urological Association Clinical Guidelines on Overactive Bladder (OAB) for Urologists: A Panel Webcast

Topic: Urology
Relevant Terms: Lower Urinary Tract Symptoms (LUTS), Overactive Bladder (OAB), Pelvic Floor Muscle
Primary Audience: Urologists, urology care team providers such as physician's assistants and nurse practitioners
Launch Date: 30-Nov-12
Credits: 0.75 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Clinical Guidelines on Overactive Bladder (OAB) for Urologists

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Apply the most recent AUA clinical guideline recommendations and best practices to assess and diagnose urological symptoms
  2. Identify and maximize screening opportunities
  3. Skillfully treat and manage urological conditions

    Faculty

    E. Ann Gormley, MD
    Professor of Surgery
    Urology
    Dartmouth-Hitchcock Med. Ctr.
    Lebanon, NH
    Deborah J. Lightner, MD
    Professor of Urology
    Department of Urology
    Mayo Clinic
    Rochester, MN
    Toby C. Chai, MD, FACS
    Professor of Surgery
    Urology Division
    University of Maryland Medical Center
    Baltimore, MD


    AUA Clinical Guideline on Overactive Educational Video on OAB for Urologists

    Commercial Support Acknowledgement
    This activity was supported by an educational grant from Astellas Scientific and Medical Affairs, Inc.
     
    CME Information

    Method of physician participation in the learning process
    :
    1. Read through the CME information.
    2. Click "Enter the Activity" link at the bottom of the page.
    3. Login. If you do not have an account, you will be prompted to create one. It is recommended that you use your email address for your user name and a password when creating your account.
    4. To claim credit, complete the pre-test, view the webcast, pass the posttest with 80% accuracy and submit the evaluation.
    5. Print your certificate for documentation.

    Medium or combination of media used
    Online

    Hardware/Software Requirements
    PC-compatible computer running Windows XP, or a Macintosh computer running OS X 10.1 or later, or a Linux computer capable of running Mozilla Firefox 3.0 or later. Processor speed of 800 MHz (1GHz preferred). A minimum of 128 MB of RAM (more preferred). A modem speed of at least 56k (broadband preferred). Internet browser should be one of the following: Internet Explorer 8.0 or later, Firefox 3.0 or later, Chrome 4.0 or later, or Safari 4.0 or later. Software requirement: Adobe Acrobat Reader 9 or newer.
     
    Estimated time to complete the educational activity
    0.75 hours

    Statement of Need
    Overactive bladder (OAB), defined as 'urgency, with or without urinary incontinence, usually with frequency and nocturia,' affects 33 million men and women in the United States. Overall, up to 17% of American adults suffer from overactive bladder; yet, only 16% of patients with OAB will receive treatment.
     
    Urologists - Screening and Assessment
    Health care providers demonstrate a clear practice gap in identifying, assessing and treating OAB. For example, one study found that that even when a patient presented with new or worsening incontinence, only 19% of physicians obtained an incontinence history and only 22% conducted a physical examination. Encouragingly, outcomes data from previous continuing professional education on urological topics suggests that health care professionals are eager to learn about updated practice guideline recommendations, implement strategies for best care, and improve their practice in the assessment, diagnosis, and management of urological conditions.
     
    As the prevalence of OAB continues to increase and options for diagnosis and evidence based treatment continue to change evolve, urologists' need and interest persists for continued education on this topic continues to grow. There is continually emergent literature on OAB and urologists can utilize effective educational opportunities to continually enhance their knowledge and practice relating to OAB, and most importantly better patient outcomes.
     
    New AUA Clinical Practice Guideline on Overactive Bladder (OAB)
    To ensure consistent, high quality, evidence-based treatment of patients with OAB, the AUA released a Clinical Practice Guideline on Overactive Bladder (OAB) in May 2012. The Guideline focuses on the diagnosis and treatment of OAB and contains useful tools for providers such as a treatment algorithm. The American Board of Urology in conjunction with the AUA continues to emphasize the importance of AUA Guidelines which serve as the basis for clinical diagnostic and treatment formulation.
     
    Program Purpose and Description
    The purpose of this activity is to provide urologists with AUA's new clinical practice guideline on overactive bladder to augment their knowledge of screening methods and identification and treatment options for OAB in the convenience of their office or practice. Special emphasis will be placed on enhanced communication with patients in regards to treatment. Content will be delivered through an educational video based largely on the new AUA guideline on OAB. This activity consists of viewing the OAB video panel discussion and answering a series of questions based on the content of the video.

    Accreditation
    The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
     
    Credit Designation
    The American Urological Association designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    Evidence Based Content
    It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

    AUA Disclosure Policy
    All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
     
    Resolution of Identified Conflict of Interest
    All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
     
    • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup
    • Limit content to evidence with no recommendations
    • Introduction of a debate format with an unbiased moderator (point-counterpoint)
    • Inclusion of moderated panel discussion
    • Publication of a parallel or rebuttal article for an article that is felt to be biased
    • Limit equipment representatives to providing logistics and operation support only in procedural demonstration 

    Planners and Principal Faculty Credentials and Disclosures
    E. Ann Gormley, MD
    Dartmouth-Hitchcock Med. Ctr.
    1 Medical Center Drive
    Lebanon, NH
    Disclosures: National Institute of Health – NIDDK

    Kathryn L. Burgio, PhD
    University of Alabama at Birmingham
    Department of Medicine
    Birmingham, AL
    Disclosures:  Pfizer: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
     
    Toby C. Chai, MD, FACS
    Professor of Surgery
    Urology Division
    University of Maryland Medical Center
    Baltimore, MD
    Disclosures: Allergan: Consultant or Advisor, Scientific Study or Trial; National Institutes of Health: Scientific Study or Trial; Taris Biomedical: Other; Ion Channel, Inc.: Consultant or Advisor; New England Research Institute: Scientific Study or Trial
     
    Darryl S. Chutka, MD
    Associate Professor of Medicine
    Mayo Clinic
    Rochester, MN
    Disclosures:  Nothing to disclose
     
    Deborah J. Lightner, MD
    Mayo Clinic
    Department of Urology
    Rochester, MN
    Disclosures: Nothing to disclose
     
    Elspeth McDougall, MD, FRCSC, MHPE
    Associate Dean of Continuing Z& Simulation Medical Education
    Director, Minimally Invasive Surgery Education Center
    Chair, AUA Office of Education
    University of California – Irvine
    Irvine, CA
    Disclosures: Ethicon Endo-Surgery: Other; Karl Storz Endoscopy American: Other
     
    Harriette Miles Scarpero, MD
    St. Thomas Hospital
    Medical Plaza East
    Nashville, TN
    Disclosures: Pfizer, Inc.: Scientific Study or Trial; American Medical Systems (AMS): Consultant or Advisor; Allergan: Consultant or Advisor, Meeting Participant or Lecturer; Warner Chilcott: Meeting Participant or Lecturer

    Abid Khan, MHS
    American UrologicalAssociation
    Health Policy:Guidelines
    Linthicum, MD 
    Disclosures:Nothing to disclose
     
    Off-label or Unapproved Use of Drugs or Devices
    It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

    Disclaimer
    The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

    Copyright
    © 2012 American Urological Association Education and Research, Inc.®

    Privacy Policy
    http://www.auanet.org/content/education-and-meetings/statements-and-policies.cfm?sub=confidentiality

    Contact
    cme@AUAnet.org